TD Cowen lowered the firm’s price target on Cerence (CRNC) to $23 from $35 and keeps an Outperform rating on the shares. Fiscal Q4 results were better than expected and fiscal Q1 and FY24 guidance ranges were also stronger than expected, though the acceleration of about $68M of deferred revenue from the early termination of the company’s “Legacy” Toyota (TM) contract “somewhat skews the strong guidance,” the analyst tells investors. Another relative negative data point announced with results was the lowering the company’s medium-term revenue outlook, the analyst added.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CRNC:
- Cerence materially guiding down previous 2025-26 outlook, says Evercore ISI
- Cerence targets FY25 revenue excluding Legacy $310M-$330M
- Cerence (NASDAQ:CRNC) Gains on Strong Q4 Revenue Growth
- Cerence Announces Fourth Quarter and Fiscal Year 2023 Results
- Options Volatility and Implied Earnings Moves Today, November 27, 2023